Since our immunohistochemical analysis demonstrated that DDR2 was associated with chemotherapy resistance in breast cancer, we subsequently verified the possible contribution of DDR2 to breast cancer chemoresistance using both chemoresistant breast cancer cell lines (M-EPIR and 231-EPIR) and chemosensitive (parental) breast cancer cell lines. Here, DDR2 is linked to breast carcinoma.